Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.

Hajiev, Saur; Allara, Elias; Motedayеn Aval, Leila; Arizumi, Tadaaki; Bettinger, Dominik; Pirisi, Mario; Rimassa, Lorenza; Pressiani, Tiziana; Personeni, Nicola; Giordano, Laura; Kudo, Masatoshi; Thimme, Robert; Park, Joong-Won; Taddei, Tamar H; Kaplan, David E; Ramaswami, Ramya; Pinato, David J; Sharma, Rohini

View / Open Files

Bibliographic metadata (XML, 16Kb)

Published version (PDF, 203Kb)

Authors

Hajiev, Saur

Allara, Elias

Motedayеn Aval, Leila

Arizumi, Tadaaki

Bettinger, Dominik

Pirisi, Mario

Rimassa, Lorenza

Publication Date

2021-04

Journal Title

Br J Cancer

ISSN

0007-0920

Publisher

Springer Science and Business Media LLC

Volume

124

Issue

Pages

1611-1611

Language

Type

Other

This Version

VoR

Metadata

Show full item record

Citation

Hajiev, S., Allara, E., Motedayеn Aval, L., Arizumi, T., Bettinger, D., Pirisi, M., Rimassa, L., et al. (2021). Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study.. [Other]. https://doi.org/10.1038/s41416-020-01241-5

Abstract

A Correction to this paper has been published: https://doi.org/10.1038/s41416-020-01241-5

Keywords

Correction, /692/699/67/1059/602, /692/4028/67/1504/1610/4029, correction

Identifiers

s41416-020-01241-5, 1241

External DOI: https://doi.org/10.1038/s41416-020-01241-5

This record's DOI: https://doi.org/10.17863/CAM.81012

Rights

Licence:

http://creativecommons.org/licenses/by/4.0/

Statistics

Total file downloads (since January 2020). For more information on metrics see the IRUS guide.